Basal cell carcinoma - Kansinòm Selil Bazal https://en.wikipedia.org/wiki/Basal-cell_carcinoma
Kansinòm Selil Bazal (Basal cell carcinoma) se kalite kansè po ki pi komen. Li souvan parèt tankou yon zòn san doulè leve soti nan po difisil. Lezyon an ka klere epi li ka gen ti veso sangen k ap pase sou li. Li ka prezante tou kòm yon zòn leve soti vivan ak ilsè. Kansè selil bazal (Basal cell carcinoma) grandi tou dousman epi li ka domaje tisi ki antoure l, men li pa gen anpil chans pou l lakòz metastaz oswa lanmò.

Faktè risk yo enkli ekspoze a limyè iltravyolèt, terapi radyasyon, ekspoze alontèm nan asenik ak fonksyon sistèm iminitè pòv (egzanp transplantasyon ògàn). Ekspozisyon nan limyè UV pandan anfans se patikilyèman danjere.

Apre dyagnostik pa byopsi, tretman se tipikman pa retire chirijikal. Sa a ka pa eksizyon senp si kansè a piti; Si kansè a pa piti, operasyon Mohs jeneralman rekòmande.

Kansè selil bazal (Basal cell carcinoma) reprezante omwen 32% nan tout kansè nan mond lan. Nan kansè po ki pa melanom, apeprè 80% se kansè selil bazal (Basal cell carcinoma). Ozetazini, apeprè 35% nan gason blan ak 25% nan fi blan yo afekte pa kansè selil bazal (Basal cell carcinoma) nan kèk pwen nan lavi yo.

○ Dyagnostik ak Tretman
#Dermoscopy
#Skin biopsy
#Mohs surgery
Plis enfomasyon ― Kreyòl ayisyen
References Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management 26029015 
NIH
Basal cell carcinoma (BCC) se kalite kansè po ki pi komen. Ekspozisyon limyè solèy la se kòz prensipal la. Prèske tout ka BCC yo montre siyn Hedgehog signaling twò anpil nan analiz molekilè a. Gen diferan tretman ki disponib epi yo chwazi selon risk repetisyon, enpòtans pou prezèvasyon tisi, preferans pasyan yo, ak limit maladi a.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
 Update in the Management of Basal Cell Carcinoma 32346750 
NIH
Basal cell carcinomas se kalite kansè po ki pi komen nan granmoun po ki gen laj 50 an oswa pi wo. Nimewo yo ap ogmante atravè lemond, sitou akòz ekspoze a limyè solèy la. Sèten kondisyon jenetik ka fè moun ki gen tandans devlope kansè sa yo nan yon laj pi piti. Basal cell carcinomas varye nan severite, sòti nan blesi supèrfisyèl oswa nodulè fasil pou trete yo rive nan blesi ki pi vaste ki mande pou diskisyon nan ekip medikal espesyalize. Pronòstik depann de chans pou kansè nan retounen oswa kapasite li nan domèn tisi ki tou près. Operasyon se tretman estanda pou pifò ka yo, asire retire egzak ak chans ki ba pou repetition. Metòd mwò pwogrese ka efektifman trete blesi supèrfisyèl.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
 European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023 37604067
Tretman prensipal la pou BCC se operasyon. Pou BCC ki gen gwo risk oswa ki repete, espesyalman nan zòn kritik yo, yo rekòmande operasyon mikwografik kontwole. Pasyan ki gen BCC supèrfisyèl ki gen anpil risk ta ka konsidere tretman topikal (topical treatments) oswa metòd destriktif. Terapi fotodinamik travay byen pou BCCs nodilè supèrfisyèl ak ki ba risk. Pou BCC lokalman avanse oswa metastatik, yo rekòmande inhibiteurs Hedgehog (vismodegib, sonidegib). Si gen pwogresyon maladi oswa entolerans nan inibitè Hedgehog, yo ka konsidere imunoterapi ak anti-PD1 antibody (cemiplimab). Radyoterapi se yon bon opsyon pou pasyan ki pa ka fè operasyon, espesyalman pasyan ki pi gran yo. Elektwochimyoterapi ta ka konsidere si operasyon oswa radyoterapi se pa yon opsyon.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.